Albert Labs CEO Dr Michael Raymont joined Proactive's Stephen Gunnion with details of the company's listing on the Canadian Securities Exchange on March 10, 2022, under the ticker 'ABRT'.
Raymont telling Proactive that cash raised in the listing will be put towards starting trials this summer and run them through to completion later this year.
He said the listing is also a milestone, marking progress along the company's path to deliver safe and effective medicines for anxiety and depression.